These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 26580452)

  • 1. Translational Insights Into Peroxisome Proliferator-Activated Receptors in Experimental Acute Pancreatitis.
    Huang W; Szatmary P; Wan M; Bharucha S; Awais M; Tang W; Criddle DN; Xia Q; Sutton R
    Pancreas; 2016 Feb; 45(2):167-78. PubMed ID: 26580452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
    Menendez-Gutierrez MP; Roszer T; Ricote M
    Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
    Aleshin S; Strokin M; Sergeeva M; Reiser G
    Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
    Derosa G; Sahebkar A; Maffioli P
    J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
    O'Sullivan SE
    Br J Pharmacol; 2007 Nov; 152(5):576-82. PubMed ID: 17704824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS; Cooper HL; Healy E
    Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARs as targets for metabolic and cardiovascular diseases.
    Cheng PT; Mukherjee R
    Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PPARs: structure, mechanisms of action and control. Note I].
    Filip-Ciubotaru F; Foia L; Manciuc C; Grigore C
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):477-84. PubMed ID: 21870744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis.
    Lamichane S; Dahal Lamichane B; Kwon SM
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29565812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
    Cheang WS; Tian XY; Wong WT; Huang Y
    Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.
    Di Paola R; Cuzzocrea S
    Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):157-75. PubMed ID: 17394034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA; Piqueras L; Bishop-Bailey D
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.